ArticleESMO real world data and digital oncology2024
UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer.
Article in ESMO real world data and digital oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Review
- Article
- Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.Oncology and therapy · 2026Article
- MCV-Neutropenia Risk Score and Overall Survival in HR+/HER2- Advanced Breast Cancer: A Multicenter Retrospective Landmark Analysis.Breast cancer (Dove Medical Press) · 2026Article
- Clinical outcomes and toxicity in metastatic breast cancer patients treated with first or second-line cyclin-dependent kinase (CDK) 4/6 inhibitors and endocrine therapy in Egypt.The Pan African medical journal · 2026Observational
- First-line CDK4/6 inhibitor treatment of HR-positive, HER2-negative metastatic breast cancer: real-world data from Ho Chi Minh City Oncology Hospital, Vietnam.Frontiers in oncology · 2026Article
- Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2- advanced/metastatic breast cancer: updated systematic review.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are widely used to treat hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). This study aimed to capture the real-world efficacy and tolerability of CDK 4/6is. Patients and methods: Data were retrospectively collected from five centres in South West England between April 2017 and November 2022. Results: Six hundred and sixty-six patients were included (median age 66 years; interquartile range 23-92 years). Five hundred and forty-four (82.7%) were treated with CDK4/6i as first-line therapy and 122 (18.3%) as second-line therapy. Median follow-up time was 28 months (range 0-76 months). Five hundred and thirty-seven received palbociclib (80.6%), 85 patients received abemaciclib (12.8%) and 44 received ribociclib (6.6%). Palbociclib and ribociclib most frequently caused neutropenia (38.2% and 26.4%, respectively) whilst abemaciclib caused diarrhoea (61.2%). Rates of dose reduction (DR) (between 53.8% and 59.2%) and time to first DR were similar for all agents (2-3 cycles). For first-line therapy, median progression-free survival (PFS) was 31 months (25-35 months) for palbociclib, 16 months [9 months-not reached (NR)] for abemaciclib and 44 months (21-NR) for ribociclib. Median overall survival (OS) was 47 months (41 months-NR) for palbociclib and was not reached for abemaciclib or ribociclib. Low patient numbers precluded analysis of second-line therapy. On multivariate analysis, visceral metastases and Eastern Cooperative Oncology Group performance status were associated with shorter PFS and OS, whilst DR was associated with longer PFS and OS. Conclusion: These data demonstrate that CDK4/6is are an effective and safe treatment for metastatic HR+/HER2- breast cancer. Efficacy was in line with trial data and other real-world data. DR was associated with improved PFS and OS, suggesting that trials of CDK4/6is at a lower starting dose are warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.